Adapting detection sensitivity based on evidence of irregular sinus arrhythmia to improve atrial fibrillation detection in insertable cardiac monitors

Helmut Pürerfellner1*, Prashanthan Sanders2, Shantanu Sarkar3, Erin Reisfeld3, Jerry Reiland3, Jodi Koehler3, Evgeny Pokushalov4, L’uboš Urban5, and Lukas R.C. Dekker6

1Department of Cardiology, Public Hospital Elisabethinen, Academic Teaching Hospital, Ordensklinikum A-4020 Linz, Fadingerstraße 1, Austria; 2Department of Cardiology, Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia 5005, Australia; 3Research and Development, Cardiac Rhythm and Heart Failure, Medtronic Plc., Moundsview, MN, 55112, USA; Moundsview, MN, USA; 4Arrhythmia Department and Electrophysiology Laboratory, State Research Institute of Circulation Pathology, Rechkunovskaya 15, Novosibirsk, 630055, Russia Research Institute of Circulation Pathology, Novosibirsk, Russia; 1Department of Arrhythmias and Cardiac Pacing, The National Institute of Cardiovascular Diseases, Pod Krížou hórkou 1, 833 48 Bratislava 37, Slovakia; and 6Department of Cardiology, Catharina Hospital, Michelangeloalaan 2, 5623 EJ Eindhoven, The Netherlands

Received 31 March 2017; editorial decision 21 July 2017; accepted 27 July 2017; online publish-ahead-of-print 3 October 2017

Aims
Intermittent change in p-wave discernibility during periods of ectopy and sinus arrhythmia is a cause of inappropriate atrial fibrillation (AF) detection in insertable cardiac monitors (ICM). To address this, we developed and validated an enhanced AF detection algorithm.

Methods and results
Atrial fibrillation detection in Reveal LINQ ICM uses patterns of incoherence in RR intervals and absence of P-wave evidence over a 2-min period. The enhanced algorithm includes P-wave evidence during RR irregularity as evidence of sinus arrhythmia or ectopy to adaptively optimize sensitivity for AF detection. The algorithm was developed and validated using Holter data from the XPECT and LINQ Usability studies which collected surface electrocardiogram (ECG) and continuous ICM ECG over a 24–48 h period. The algorithm detections were compared with Holter annotations, performed by multiple reviewers, to compute episode and duration detection performance. The validation dataset comprised of 3187 h of valid Holter and LINQ recordings from 138 patients, with true AF in 37 patients yielding 108 true AF episodes ≥2-min and 449 h of AF. The enhanced algorithm reduced inappropriately detected episodes by 49% and duration by 66% with <1% loss in true episodes or duration. The algorithm correctly identified 98.9% of total AF duration and 99.8% of total sinus or non-AF rhythm duration. The algorithm detected 97.2% (99.7% per-patient average) of all AF episodes ≥2-min, and 84.9% (95.3% per-patient average) of detected episodes involved AF.

Conclusion
An enhancement that adapts sensitivity for AF detection reduced inappropriately detected episodes and duration with minimal reduction in sensitivity.

Keywords
Atrial fibrillation • Insertable cardiac monitors • Diagnosis and monitoring

* Corresponding author. Tel: +43 732 7676 4917; fax: +43 732 7676 2106. E-mail address: helmut.puererfellner@ordensklinikum.at

© The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
**What's new?**
- Identified that intermittent ineffectiveness of p-wave sensing as a cause of inappropriate AF detection in insertable cardiac monitor (ICM) employing p-wave sensing to reject inappropriate detections during periods of RR irregularity.
- Developed a new method to identify presence of runs of ectopy or sinus arrhythmia in patients based on patterns in RR interval irregularity and presence of single p-wave between two r-waves.
- Developed a new method of adapting atrial fibrillation (AF) detection sensitivity with time based on what the device learns about the presence of runs of ectopy or sinus arrhythmia in patients on an ongoing basis.
- Validated improved performance of AF detection in insertable cardiac monitors using the enhanced algorithm.
- Provided perspectives on how to interpret AF detection performance results in ICM devices.

**Introduction**

Subcutaneous insertable cardiac monitors (ICM) have been shown to be clinically useful for continuous long-term diagnosis and monitoring of atrial fibrillation (AF) after surgical or catheter AF ablation, atrial flutter ablation, and to investigate cryptogenic stroke. The clinical goal of AF detection in an ICM is to determine if a patient has AF and quantify the amount or burden of AF. Several studies have shown that knowing the relevant amount of AF may be clinically important. While ICMs have been shown to have high accuracy in quantifying AF burden, one hindrance for using ICMs has been the inappropriate AF detection caused by runs of atrial ectopy with irregular coupling intervals and sinus arrhythmia. Most of these inappropriate detections are short in duration and do not significantly affect the accuracy of AF burden; however, they do increase the clinical workload required to review these episodes. The AF detection algorithm in the Reveal LINQ™ ICM looks for incoherence in an RR interval time series and absence of evidence of a single p-wave between two r-waves to detect AF. The addition of p-wave evidence was shown to significantly improve performance of the original RR interval based algorithm. Intermittent ineffectiveness of ascertaining p-wave evidence under certain circumstances may lead to detection of short duration inappropriate episodes, particularly in patients with sinus arrhythmia or long runs of atrial ectopy with irregular coupling. The main goal of this study is to develop and validate an enhanced algorithm designed to improve AF detection in ICMs based on adapting the sensitivity for AF detection over time based on detecting the presence of irregular sinus rhythm.

**Methods**

**Algorithm design**

Figure 1 shows the basic schematic of AF detection in the predicate Reveal LINQ ICM along with the components of the algorithm enhancement described in this study. The enhanced AF detection algorithm is implemented in three steps. In the first step, the algorithm looks for patterns of incoherence in a Lorenz plot of difference in RR intervals to compute an AF evidence score every 2 min. As has been discussed in earlier studies, the 2-min detection period was a deliberate choice based on significant improvement of algorithm performance for a detection period of 2 min compared with 30 s. This is the original AF detection algorithm utilized in the predicate Reveal XT ICM. As has been discussed in earlier studies, the 2-min detection period was a deliberate choice based on significant improvement of algorithm performance for a detection period of 2 min compared with 30 s. Figure 2 shows a patient record of 10 h with sinus arrhythmia and runs of ectopy, a challenging case for the AF detection algorithm. Figure 2A illustrates how this AF evidence score obtained from the Lorenz plot can be compared with a threshold to detect AF. In this example, AF evidence score derived from
Lorenz plot is above threshold for significant amount of time, thus detecting AF inappropriately. Electrocardiogram (ECG) and RR interval record from segment A in Figure 2 shows an example of inappropriate AF detection using the Lorenz plot algorithm by itself.

The second step of the algorithm comprises of reducing the AF evidence score derived from Lorenz plot by a P-wave evidence score (P-Sense) before comparison to a threshold to detect AF14,15 as illustrated in Figure 2B. The P-Sense component of the algorithm is implemented in the predicate Reveal LINQ ICM device. The P-wave evidence score is computed based on the presence of a single P-wave and absence of atrial flutter waves or noise between two r-waves.14 Electrocardiogram and RR interval record from segment A in Figure 2 shows an example of inappropriate AF detection using the Lorenz plot alone being successfully rejected by the P-Sense algorithm. While the P-Sense algorithm is able to reduce a significant number of inappropriate detections, intermittent ineffectiveness of P-Sense during prolonged duration of sinus arrhythmia or runs of ectopy may still lead to detection of inappropriate episodes (Figure 2B). This intermittent ineffectiveness of the P-Sense algorithm can be caused by p-wave amplitude fluctuation, baseline noise, rapid rates, or long P-R intervals. Segment B in Figure 2 shows an example of ECG and RR interval record of an inappropriately detected episode that could not be rejected by P-Sense algorithm due to presence of baseline noise and faster rates, but Adaptive P-Sense is successful in rejecting the inappropriate detection. AF, atrial fibrillation.

**Figure 2** An example to show how different steps of the Adaptive P-Sense algorithm reduces inappropriate AF episode detection in a patient with runs of ectopy and sinus arrhythmia. (A) The Lorenz plot based AF evidence score computed using only RR intervals. The score is greater than threshold for large proportion of time to generate false detections. (B) AF evidence score from Lorenz plot reduced by P-wave evidence score (P-Sense) show significant reduction of false detections. Segment A shows an example 2-min period incorrectly detected by the Lorenz plot algorithm, but rejected by the P-Sense algorithm. (C) Periods of effective P-Sense algorithm leads to accumulation of adaptive evidence. The period shown in segment A increments the adaptive evidence score. (D) AF evidence score from Lorenz plot reduced by P-wave evidence and adaptive evidence illustrates how adaptive P-Sense further reduces false detection with the modified AF evidence score below threshold for entire 10-h duration. Segment-B shows a 2-min period where P-Sense is ineffective in rejecting false detection due to presence of baseline noise and faster rates, but Adaptive P-Sense is successful in rejecting the inappropriate detection. AF, atrial fibrillation.
The P-Sense algorithm has been effective in rejecting RR interval based irregularity, i.e. when the P-Sense algorithm is effective in reducing inappropriate detection, as evidence of the presence of sinus arrhythmia or runs of ectopy (Figure 1). The algorithm accumulates evidence of presence of sinus arrhythmia or runs of ectopy in an adaptive evidence score (Figure 2C) which is used to adaptively reduce the AF evidence score over a period of time (Figures 1 and 2D). The adaptive evidence score is reset to zero on detecting a longer duration AF episode or prolonged absence of RR irregularity or p-wave evidence. Segment B in figure 2 shows an example of an episode which was inappropriately detected after application of P-Sense, but was rejected after application of adaptive P-Sense. The adaptive P-Sense algorithm will only be effective in patients where the P-Sense algorithm has been effective in rejecting RR interval based irregularity for periods of time (Figure 2B).

The adaptive P-Sense algorithm can work in a ‘nominal’ or ‘aggressive’ mode in which the adaptive evidence is accumulated faster and has a higher maximum limit. This is in addition to the difference in the P-Sense algorithm ‘nominal’ and ‘aggressive’ mode of operation as programmed by the ectopy rejection parameter. The programmable AF threshold can be set to four different values consisting of ‘more sensitive’, ‘balanced sensitivity’, ‘less sensitive’, and ‘least sensitive’ with increased specificity for AF detection from the first setting to the last setting. The AF detection parameters are assigned nominally to different thresholds at implant depending on the indication for ICM. For AF monitoring in patients with known AF the device is programmed to AF-only detection mode with the AF threshold set at ‘balanced sensitivity’ and ectopy rejection set to ‘nominal’. For example, for AF diagnosis in patients after cryptogenic stroke, the device is programmed to AF-only with a ‘balanced sensitivity’ threshold and ‘aggressive’ ectopy rejection setting.

**Dataset**

The adaptive P-Sense algorithm was developed using a subset of patients from the XPECT Holter study (NCT00680927). The first validation dataset comprised of the remaining patients from the XPECT study and second Holters where available from development set patients. The second validation dataset comprised of patient Holters from the Reveal LINQ usability study (NCT01965899). Patients were enrolled in the XPECT study if they were ablation candidates or had documented history or symptoms of AF. The Reveal LINQ Usability study had two phases, the first 30 enrolled patients with any indication for an ICM; the subsequent 121 patients with a documented history of AF and ablation candidates. In both studies, North-East Monitoring DR220 Holter recorders were used to record two leads of the patient’s surface ECG as well as the ICM ECG that was uplinked by continuous telemetry to the Holter. The XPECT patients were implanted with a Reveal XT ICM and underwent Holter monitoring for 46-h, whereas in the Usability study patients were implanted with a Reveal LINQ ICM device and Holter recording was done for 24-h. Patients from both studies were provided written informed consent, and the study protocols were reviewed and approved by the Human Research Ethics Committee of each participating institution.

The surface ECG in the Holter recording in the XPECT study was annotated by an independent core-lab cardiologist for the occurrence of AF. Two reviewers annotated the two channels of surface ECG and Reveal LINQ ECG collected in Usability study for presence of AF and atrial tachycardia (AT). All annotated AF episodes were reviewed a third time to ascertain the accuracy of the AF annotation and the onset and termination times of the episode. The reviewers were blinded to the device episode detection information during the annotation process. Holter recording segments with non-interpretable surface ECG or ICM uplink telemetry errors were excluded from the analysis. Periods of telemetry dropouts leading to periods of no uplink and storage of ICM ECG in the XPECT study and AF detection parameters in the Reveal LINQ usability study were also excluded. Segments annotated as atrial flutter were also excluded from the analysis.

**Statistical analysis**

The Holter annotations for true AF episodes were compared with the AF detections by the ICM device. The same definitions of true positive, false positive, false negative, and true negative duration were used for computation of episode and duration detection performance metrics as reported in earlier studies. Only true AF episodes that were annotated to be ≥2 min in duration were used for data analysis. Diagnostic sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of detecting the presence or absence of AF by the ICM were evaluated for the duration of the Holter recording period for each patient. Duration detection sensitivity, specificity, PPV, and NPV which measure accuracy of AF burden (cumulative AF duration per unit time), were computed for the entire Holter duration from all patients (gross average) and for each patient and then averaged across patients (patient average). Gross and patient average episode detection sensitivity and PPV were computed. Generalized estimation equation (GEE) estimates, which adjust for multiple episodes in a patient, were also computed for episode detection sensitivity and PPV.

**Results**

**Performance analysis from XPECT study population**

The XPECT study enrolled a total of 247 patients. The baseline characteristics of the enrolled patients were reported earlier. Patients had a mean age of 57 ± 10 years with 67% being male with history of paroxysmal AF in 92% and atrial flutter in 24% of patients. A total number of 208 Holter recordings were included in this analysis after exclusion of Holters with <10 h of analysable ECG due to missing telemetry and/or uninterpretable surface ECG. The development set consisted of the first 56 patients with valid Holter recordings with a total of 2162 h of valid recording time (39 h/patient). In 16 patients true AF was observed, yielding a total of 89 true AF episodes of ≥2-min and 200 h of AF. The validation set comprised of 176 patients, Holters from the remaining 152 patients and second Holters in 24 patients in the development set. The validation set had a total follow-up duration of 7271 h (41 h/patient) with true AF observed in 60 patients, yielding 393 true AF episodes ≥2 min and 990 h of AF.

The episode and duration detection performance comparison between the P-Sense and adaptive P-Sense enhancement for the development and validation datasets from the XPECT study is shown in Table 1. In the validation set, the adaptive P-Sense enhancement was able to reduce inappropriate episodes by 28% in AF monitoring and by 37% in the AF diagnosis programmable settings (with an average reduction of 32% assuming equal instances of the two programmable settings) compared with the P-Sense algorithm with <1% loss in true episodes (Figure 3). Further, the enhanced algorithm reduced inappropriately detected AF duration by 22 and 21% in the respective programming modes with minimal loss in detected true positive duration.

Table 2 shows how duration sensitivity reduces and duration specificity increases with increasing AF detection threshold from ‘More Sensitive’ to ‘Least Sensitive’ and ectopy rejection programmed to...
Table 1  Performance comparison for XPACT study development and validation set between predicate AF detection algorithm (P-Sense) and adaptive P-Sense (aP-Sense) algorithm enhancement for two programmable setting most often used for AF diagnosis and monitoring

| Performance metrics | Development dataset (N = 56) | Validation dataset (N = 176) |
|---------------------|-------------------------------|------------------------------|
|                     | AF monitoring                | AF diagnosis                 | AF monitoring | AF diagnosis |
|                     | P-sense | aP-sense | P-sense | aP-sense | P-sense | aP-sense | P-sense | aP-sense |
| True positive episodes (Pts) | 79 (16) | 79 (16) | 76 (16) | 76 (16) | 332 (56) | 330 (56) | 331 (56) | 328 (56) |
| False positives episodes (Pts) | 112 (7) | 57 (7) | 68 (7) | 36 (7) | 253 (23) | 183 (22) | 196 (20) | 124 (17) |
| True positive duration in hours | 196 | 195 | 195 | 195 | 969 | 969 | 967 | 967 |
| False positive duration in hours | 11 | 11 | 8 | 41 | 32 | 33 | 26 | 28 |
| Episode sensitivity | Gross | 88.8% | 88.8% | 85.4% | 85.4% | 84.5% | 84.0% | 84.2% | 83.5% |
|                     | Patient average | 97.2% | 97.2% | 96.3% | 96.3% | 88.1% | 88.0% | 88.1% | 87.8% |
|                     | GEE (95% CI) | 96.8% | 96.8% | 96.3% | 96.3% | 87.9% | 87.7% | 87.8% | 87.3% |
|                     | (81.2–99.5) | (81.2–99.5) | (78.4–99.5) | (78.4–99.5) | (79.6–93.1) | (79.4–93.0) | (79.5–93.0) | (79.1–92.6) |
| Episode PPV | Gross | 39.8% | 56.2% | 55.3% | 70.0% | 54.4% | 62.1% | 61.7% | 71.7% |
|                     | Patient average | 76.2% | 76.2% | 76.3% | 76.3% | 76.5% | 77.7% | 79.8% | 83.8% |
|                     | GEE (95% CI) | 76.2% | 76.2% | 76.3% | 76.4% | 76.5% | 77.6% | 79.8% | 83.7% |
|                     | (55.4–89.2) | (55.4–89.2) | (55.5–89.3) | (55.7–89.3) | (66.1–84.5) | (67.2–85.4) | (69.5–87.3) | (73.8–90.3) |
| Duration sensitivity | Gross | 98.0% | 98.0% | 97.0% | 97.0% | 97.8% | 97.8% | 97.7% | 97.7% |
|                     | Patient average | 93.6% | 93.5% | 92.0% | 92.0% | 86.6% | 86.5% | 86.4% | 86.3% |
| Duration specificity | Gross | 99.1% | 99.4% | 99.4% | 99.6% | 99.3% | 99.5% | 99.5% | 99.6% |
|                     | Patient average | 95.4% | 95.8% | 95.8% | 96.0% | 92.5% | 92.6% | 92.1% | 92.2% |
| Duration PPV | Gross | 92.0% | 94.7% | 94.7% | 96.1% | 95.9% | 96.8% | 96.7% | 97.4% |
|                     | Patient average | 74.2% | 74.2% | 75.2% | 75.2% | 78.9% | 80.1% | 81.4% | 85.3% |
| Duration NPV | Gross | 99.8% | 99.8% | 99.7% | 99.7% | 99.6% | 99.6% | 99.6% | 99.6% |
|                     | Patient average | 96.1% | 96.1% | 96.0% | 96.0% | 91.9% | 91.9% | 91.9% | 91.9% |

Adapting sensitivity for AF detection in ICM

‘aggressive’ compared with ‘nominal.’ Similarly episode detection sensitivity reduces and episode detection PPV increases with increasing AF detection threshold and more aggressive ectopy rejection programming (Table 2). In the overall dataset of 208 patients in the AF monitoring setting, the adaptive P-Sense algorithm detected AF in 76 patients with AF and 14 of 132 patients with no AF on Holter monitor. Further, in 87 patients with device detected AF, 73 also had AF in Holter and in the remaining 132 patients with no device detected AF, 3 had AF in Holter.

Performance analysis from the Reveal LINQ usability study population

The Reveal LINQ usability study enrolled a total of 151 patients. The baseline characteristics of the enrolled patients were reported earlier. Patients had a mean age of 57 ± 12 years with 67% being male with a history of paroxysmal AF in 67%, and atrial flutter in 16% of patients. The indication for ICM implant was unexplained syncope 13%, cryptogenic stroke in 1%, palpitations or suspected AF in 5%, and AF ablation or AF management in 81%. After exclusion of recorded segments with missing telemetry or uninterpretable surface ECG and periods of AT, this second validation dataset comprised of valid Holter recordings from 138 patients with a total follow-up duration of 3187 h (23 h/patient) with true AF observed in 37 patients, yielding 108 true AF episodes ≥2 min and 449 h of AF.

The episode and duration detection performance comparison between the P-Sense and adaptive P-Sense enhancement for the second validation dataset from the Reveal LINQ usability study is shown in Table 3. The adaptive P-Sense enhancement was able to reduce inappropriately detected episodes by 49% compared with the P-Sense algorithm with <1% loss in true positives (Figure 3). Further the enhanced algorithm reduced inappropriately detected AF duration by 66% with minimal loss in detected true positive duration. The gross duration sensitivity and specificity performance means that if there are 100 h of true AF the algorithm detected 98.9 h as AF, and if there are 100 h of normal sinus or other non-AF rhythms the algorithm inappropriately detected only 0.2 h as AF. The overall duration (or AF burden) accuracy, defined as total correctly identified duration, was 99.7%.

The gross episode detection performance implies that the enhanced algorithm detected 97 of every 100 episodes of true AF...
In duration, and of every 100 episodes detected across patients, 85 of them had true AF. The patient average and the GEE estimation numbers imply that <0.3% of patients with true episodes will be missed and <5% of patients with detected episodes will have only false episodes. For all detected episodes (>2-min) the ‘gross’ episode PPV was 85% and it improved to 93, 96, 97, 99, and 100% for detected episodes >6, 10, 20, 30, and 60 min respectively. Thus, if the algorithm detects an AF episode which is >1-h, it is close to 100%

Table 2

| Ectopy rejection programming | Nominal |  |  |  |  |  |  |  |  |
|-----------------------------|---------|---|---|---|---|---|---|---|---|
|                             | More sensitive (%) | Balanced sensitivity (%) | Less sensitive (%) | Least sensitive (%) | More sensitive (%) | Balanced sensitivity (%) | Less sensitive (%) | Least sensitive (%) |
| AF detection threshold      | 98.0     | 97.8 | 97.6 | 96.3 | 97.9 | 97.7 | 97.3 | 94.9 |
| AF detection threshold      | 99.3     | 99.5 | 99.6 | 99.7 | 99.5 | 99.6 | 99.6 | 99.7 |
| AF diagnosis                | 84.7     | 84.0 | 82.7 | 76.6 | 84.2 | 83.5 | 81.4 | 74.3 |
| Per Device Programming      | 53.8     | 62.1 | 74.0 | 84.1 | 62.5 | 71.7 | 80.2 | 86.7 |

Figure 3 Number of true AF episodes that are detected and number of falsely detected AF episodes before and after application of adaptive P-Sense algorithm. Significant reduction of false detections was achieved in development and both validation sets with minimal reduction in true detections. AF, atrial fibrillation.
likely that episode is a true AF episode. The longest inappropriate detection was 48 min in duration in this study.

After application of the adaptive P-Sense algorithm the device identified patients having AF in 37 of 37 patients with AF (diagnostic sensitivity of 100%), and in 1 out of 101 patients with absence of AF in their 24 h Holter recordings (diagnostic specificity of 99%). The algorithm identified 38 patients with AF of which 37 had AF in Holter recordings (diagnostic PPV of 97%), and 100 patients to not have any AF of which 100 patients also had no AF in their Holter recordings (diagnostic NPV of 100%).

### Discussion

The results of the adaptive P-Sense algorithm enhancement for AF detection in Reveal LINQ ICM as shown by the Reveal LINQ usability study data can be summarized as follows: It is expected to reduce false episodes by 49% and false duration by 66% without significantly reducing true episodes and true duration. In addition, the enhanced algorithm appropriately detected close to 99% of total AF duration and over 99.8% of total sinus or non-AF rhythm duration. Taking only AF episodes ≥2 min in length, 97% (99.7% patient average) were correctly classified. Finally, 85% of all detected episodes (95% patient average) and 100% of detected episodes ≥1 h had AF.

There are certain perspectives to consider while interpreting the results presented in this study as well as other similar studies. The performance of AF detection in ICM devices, particularly the diagnostic metrics and episode and duration detection metrics such as PPV and NPV, depend significantly on the patient population, incidence rate of AF, the duration of monitoring and the type of AF. For example, diagnostic sensitivity will get closer to 100% for longer monitoring duration for the study or in studies that are more likely to have higher proportion of patients with persistent AF,15–17 The overall AF detection algorithm performance improves for longer duration of AF hence it would perform better in patients with persistent AF compared with paroxysmal AF. In the XPECT study, done in the earlier days of AF ablation, more than 92% of patients had a history of paroxysmal AF compared with 67% in the LINQ Usability study. The XPECT study had more shorter duration episodes that are more likely to be missed due to the asynchronous nature of the 2-min detection periods. Further, episode detection PPV will be highly dependent on incidence rate of AF in the patient cohort and number of incidences of inappropriate termination and re-detection of the same true episode. The performance metrics which may be most applicable across patient cohorts and monitoring durations are duration sensitivity and specificity and episode sensitivity. For example, high duration sensitivity in a known-AF patient cohort improves the odds of detecting AF with high sensitivity in cryptogenic stroke patients with intermittent paroxysmal AF. Maximizing duration specificity is a design consideration to reduce inappropriate detections; however that should not be achieved by compromising significantly on duration sensitivity.

The two primary patient populations where the LINQ ICM device is being used for AF diagnosis and monitoring are in cryptogenic stroke patients and in AF ablation/AF management patients, respectively. The performance results presented in this study is primarily from patients with known history of AF, i.e. in ablation/AF management patient cohort. Both the XPECT13 and the Reveal LINQ usability15 Holter study were performed in this patient cohort as they provided for the best chance of having patients with AF during the day of Holter recording and evaluating the sensitivity of AF detection. The AF incidence is very low in cryptogenic stroke patient population and a very large study will be needed to have sufficient Holters with AF in this patient cohort. Some performance metrics in other patient cohorts was recently reported from a real-world study.18 A similar study could be performed to evaluate the prospective effectiveness of the adaptive P-Sense algorithm in patients with cryptogenic stroke.

Besides the higher incidence of paroxysmal AF in XPECT study, there are some other technical differences between these two studies which affect performance results. The XPECT study was performed with Reveal XT devices with no standard implant procedure. Many false detections and missed detections are attributed to a loose implant pocket where the device can move in the pocket leading to electrodes losing contact. For example, a large proportion of missed AF episodes in the XPECT are attributed to loss of contact and no measured ECG during the AF episodes. The smaller size of the

| Performance metrics | P-sense | Adaptive P-sense |
|---------------------|---------|-----------------|
| True episodes detected (patients) | 106 (37) | 105 (37) |
| Falsely detected episodes (patients) | 82 (5) | 42 (3) |
| True detected duration in hours | 444.4 | 444.3 |
| Falsely detected duration in hours | 13.1 | 4.4 |
| Episode sensitivity (%) | | |
| Gross | 98.1% | 97.2% |
| Patient average | 99.8% | 99.7% |
| GEE (95% CI) | 97.1% | 94.2% | (97.0–97.1) | (94.1–94.2) |
| Episode PPV (%) | | |
| Gross | 74.4% | 84.9% |
| Patient Average | 90.4% | 95.3% |
| GEE (95% CI) | 90.4% | 95.1% | (77.6–96.2) | (83.2–98.7) |
| Duration sensitivity (%) | | |
| Gross | 98.9% | 98.9% |
| Patient average | 96.7% | 96.7% |
| Duration specificity (%) | | |
| Gross | 99.5% | 99.8% |
| Patient average | 99.6% | 99.8% |
| Duration PPV (%) | | |
| Gross | 97.1% | 99.0% |
| Patient average | 90.6% | 95.4% |
| Duration NPV (%) | | |
| Gross | 99.8% | 99.8% |
| Patient average | 98.8% | 98.8% |
device, standardized technique to form a tight pocket, and improved electrode coating all improved signal quality in the LINQ device which was used in the Usability study reducing the loss of contact related performance issues significantly. Thus the performance of the adaptive P-Sense algorithm in the Usability study is more applicable. The XPECT study had fewer telemetry errors in the uplinked ECG and hence it was useful in the development and validation of the algorithm across all programmable settings.

**Limitations**

The primary limitation of this study is that the Holter studies were done only for the duration of 24 or 48 h and hence some of the performance results, particularly the diagnostic metrics, may not apply for a longer duration of monitoring. The longer the monitoring duration the more likely the device will detect AF in a patient either appropriately or inappropriately. Another limitation of this study is that it does not address the ability of the algorithm to detect atrial flutter or AT, and AF episodes that are <2 min in duration. The reasons for these exclusions include low incidence of atrial flutter in the studies, AF-only mode being the nominal mode of operation of the device and a 2-min detection period used by the algorithm.

**Conclusion**

An enhanced algorithm that adapts the sensitivity for AF detection over time based on evidence of irregular sinus is developed and validated using data from multiple Holter study data. This algorithm substantially reduces inappropriately detected episodes and duration with minimal reduction in sensitivity for detecting AF.

**Acknowledgements**

The authors would like to thank Mae Chao for implementation of the algorithm and Katherine Lindborg for help with manuscript preparation.

**Funding**

This work was supported by Medtronic, Plc.

**Conflict of interest:** H.P.: Consultancy fees from Medtronic, Saint Jude Medical, Biosense Webster; Honoraria: Boston Scientific, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Sanofi, P.S.: Advisory board, research funding, lecture honoraria and/or consulting fees from Biosense-Webster, Medtronic, St Jude Medical, Boston Scientific, Biotronik, Sorin and CathRx. Financial support from the National Health and Medical Research Council of Australia and the National Heart Foundation of Australia. S.S., E.R., J.R., and J.K. are employees and owner of stocks of Medtronic, Plc. E.P.: Honoraria: Medtronic, Biosense Webster and Boston Scientific; L.U.: Consultancy fees: Medtronic, Saint Jude Medical, Bayer, Boehringer-Ingelheim, GSK, Novartis. Honoraria: Medtronic, Bayer, Boehringer-Ingelheim, Pfizer, GSK, Novartis. L.R.C.D.: Consultancy fees from Medtronic, Philips, Boston Scientific. Research support by Medtronic.

**References**

1. Hanke T, Chantos EI, Steele U, Karluss A, Kratzel E, Graf B et al. Twenty-four-hour holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy: up to 12-months experience with a novel permanently implantable heart rhythm monitor device. Circulation 2009;120:5177–84.
2. Pokushalov E, Romanov A, Carbuggi G, Artymovenko S, Turov A, Shirokova N et al. Use of an implantable monitor to detect arrhythmia recurrences and select patients for early repeat catheter ablation for atrial fibrillation: a pilot study. Circ Arhythm Electrophysiol 2011;4:823–31.
3. Verma A, Champigne J, Sapp J, Essebag V, Novak P, Skanes A et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013;173:149–56.
4. Kapa S, Epstein AE, Callans DJ, Garcia FC, Lin D, Bala R et al. Assessing arrhythmia burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS study. J Cardiovasc Electrophysiol 2013;24:875–81.
5. Mittal S, Pokushalov E, Romanov A, Ferrara M, Arshad A, Musat D et al. Long-term ECG monitoring using an implantable loop recorder for the detection of atrial fibrillation after cavotricuspid isthmus ablation in patients with atrial flutter. Heart Rhythm 2013;10:1598–604.
6. Egeth T, Hochreiter M, Mundel M, Freudenberger T. Insertable cardiac event recorder in detection of atrial fibrillation after cryptogenic stroke: an audit report. Stroke 2013;44:2007–9.
7. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Marillo CA et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478–86.
8. Ziegler PD, Rogers JD, Ferreira SW, Nichols AJ, Sarkar S, Koehler JL et al. Real-world experience with insertable cardiac monitors to find atrial fibrillation in cryptogenic stroke. Cerebrovasc Dis 2015;40:175–81.
9. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arhythm Electrophysiol 2009;2:474–80.
10. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120–9.
11. Sarkar S, Koehler J, Crossley GH, Tang WH, Abraham WT, Warman EN et al. Burden of atrial fibrillation and poor rate control detected by continuous monitoring and the risk for heart failure hospitalization. Am Heart J 2012;164:616–24.
12. Sarkar S, Ritchie D, Mehta R. A detector for a chronic implantable atrial tachyarrhythmia monitor. IEEE Trans Biomed Eng 2008;55:1219–24.
13. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial. Circ Arhythm Electrophysiol 2010;3:141–7.
14. Pürerfellner H, Pokushalov E, Sarkar S, Koehler J, Zhou R, Urban L et al. P-wave evidence as a method for improving algorithm to detect atrial fibrillation in insertable cardiac monitors. Heart Rhythm 2014;11:1575–83.
15. Sanders P, Pürerfellner H, Pokushalov E, Sarkar S, Di Bacco M, Maus B et al. Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: results from the Reveal LINQ Usability study. Heart Rhythm 2016;13:1425–32.
16. Ciconte G, Saviano M, Giannelli L, Calovic Z, Baldi M, Caccio C et al. Atrial fibrillation detection using a novel three-vector cardiac implantable monitor: the atrial fibrillation detection study. Europace 2017;19:1101–08.
17. Nölker G, Mayer J, Böltz LH, Seidl K, Van Driel V, Massa T et al. Performance of an implantable cardiac monitor to detect atrial fibrillation: results of the DETECT AF study. J Cardiovasc Electrophysiol 2016;27:1403–10.
18. Mittal S, Rogers J, Sarkar S, Koehler J, Warman EN, Tomson TT et al. Real-world performance of an enhanced atrial fibrillation detection algorithm in an insertable cardiac monitor. Heart Rhythm 2016;13:1624–30.